Long Term Promising Outcomes in Treatment of Lower Urinary Tract Symptoms Volume 2 - Issue 4

Ayse Veyhurda Dikmen*

• Consultant Urologist, Ankara, Turkey

Received: December 21, 2019;  Published: January 07, 2020

Corresponding author: Ayse Veyhurda Dikmen, MD, Consultant Urologist, Ankara, Turkey

DOI: 10.32474/GJAPM.2020.02.000142

Fulltext PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

I aimed to define the efficacy of silodosin in treatment of lower urinary tract symptoms of men and form a background for a nomogram for Turkish population.

Materials and Methods: Responses of treatment of 1600 male patients attending outpatient urology clinic with lower urinary tract symtoms between March 2013 and March 2019 were evaluated retrospectively. The patients were between 41 and 97, mean age of whom was 63,1±2,3 with serum total PSA level being under 4ng/dl and benign digital rectal examination findings, none of them, getting any α-blocker for at least one month by the time of outpatient clinic attending. The patients who have been treated with silodosin for 9 months due to benign prostatic hyperplasia (BPH) were evaluated retrospectively with their pretreatment and posttretment results of Qmax (maximum flow rate), IPSS (International Prostate Symptom Score), IIEF (International Index of Erectile Function) and PVR (postvoiding residue).

Results: Pretreatment and posttreatment basal PSA levels of the patients were 3.4±0.6 ng/ml and 3.9 ±0.7 respectively and it was not statistically significant (p=0, 2). Pre and posttreatment mean IPSS values were 23, 8±2, 4 and 14 ,5±2, 5 respectively, being statistically significant (p < 0,002)with mean Qmax values of 11, 7±2, 7ml/sec and 24, 3±2, 2ml/sec respectively (p < 0, 001). IIEF scores were 35, 4±2, 2 and 39, 3±2, 4 being measured as pre and posttreatment values, respectively (p=0, 3). Pretreatment mean PVR was 184, 4±7, 4ml/sec while the posttreatment mean value was 73, 4±21ml/sec, (p < 0, 02). The statistical analysis was made according to paired t-test on parametric variables.

Conclusion: Prominent improvements with a 9-month silodosin treatment in values of Qmax, IPSS and PVR were statistically significant, showing its efficacy but the changes in IIEF scores were not significant. This retrospective study showing the efficacy of 9-month silodosin for BPH is a promising one for future studies.

Keywords: Alfa1-adrenoblockers; Benign prostatic hyperplasia; Bladder outlet obstruction; Lower urinary tract symptoms; Silodosin

Abstract| Introduction| Materials and Methods| Results| Conclusion| References|